Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To investigate the effect of gonadotropin-releasing hormone agonist (GnRHa) pre-treatment on the clinical outcomes of fresh and frozen embryo transfers (ETs and FETs, respectively) in infertile patients with adenomyosis.
Design: Retrospective cohort study with literature review.
Setting: Peking University First Hospital.
Population: We analysed 413 cycles of 369 women with adenomyosis who underwent ETs or FETs.
Methods: We performed logistic regression analysis and meta-analysis to assess the association of GnRHa pre-treatment with the clinical outcomes of ETs and FETs.
Main Outcome Measures: The live birth rate (LBR) was compared between patients with and without GnRHa pre-treatment.
Results: The LBR was higher in the GnRHa pre-treatment group than in the non-GnRHa pre-treatment group in ETs (41.27% vs. 24.32%, p = 0.034) and FETs (40.36% vs. 20.75%, p = 0.008). The odds of achieving a live birth of women with GnRHa pre-treatment were 2.65 times higher than that of those without (95% CI: 1.19-5.92, p = 0.017) after adjusting for confounders in ETs. Similarly, the adjusted odds ratio (OR) was 2.43 (95% CI: 1.10-5.40, p = 0.029) in FETs. For the meta-analysis, eight studies met the inclusion criteria; however, only six reported the adjusted ORs. Combination of these six adjusted ORs with our results revealed that the GnRHa pre-treatment group had higher LBRs than the non-GnRHa pre-treatment group (ET: OR 1.71, 95% CI: 1.30-2.26, FET: OR 2.61, 95% CI: 1.52-4.49).
Conclusions: In women with adenomyosis, GnRHa pre-treatment may be beneficial for LBRs following both ETs and FETs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1471-0528.18026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of GnRH agonists on endometrial immune cells in patients with adenomyosis: a prospective cohort study.
BMC Med
June 2025
Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Background: Adenomyosis is associated with lower implantation and higher miscarriage rates. Studies on recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) have shown that endometrial immune cell populations play a crucial role during implantation and early pregnancy. In women with adenomyosis, improved pregnancy outcomes following assisted reproductive technologies (ART) and pre-treatment with GnRH-agonists (GnRH-a) prior to frozen embryo transfer (FET) have been reported.
View Article and Find Full Text PDFCost-Effectiveness of Interventions Related to the Treatment of Women With Polycystic Ovary Syndrome: A Scoping Review.
Int J Womens Health
May 2025
Monash Centre for Health Research and Implementation, Monash University, Melbourne, VIC, Australia.
Context: Polycystic ovary syndrome (PCOS) affects up to one-in-five reproductive-aged women and its global healthcare-related economic burden is substantial. The aim of this review was to summarise evidence of the cost-effectiveness of interventions related to the treatment of women with PCOS.
Evidence Acquisition: Six academic databases were systematically searched for relevant records.
The impact of long-acting Gonadotropin-releasing hormone agonist pretreatment on the clinical pregnancy outcomes of hormone replacement therapy-frozen embryo transfer in recurrent implantation failure patients with and without polycystic ovary syndrome: a retrospective clinical study.
BMC Pregnancy Childbirth
February 2025
Center for Reproductive Medicine and Obstetrics and Gynecology, Drum Tower Clinic Medical College of Nanjing Medical University, Nanjing, 210008, China.
Background: Several studies have demonstrated that pre-treatment with long-acting Gonadotropin-Releasing Hormone agonists (GnRHa) can significantly enhance the clinical pregnancy rate among recurrent implantation failure (RIF) patients. Investigations have also suggested that GnRHa pre-treatment could ameliorate the clinical pregnancy and live birth rates in polycystic ovary syndrome (PCOS) patients. But there is a dearth of research on whether long-acting GnRHa pre-treatment yields superior clinical outcomes for RIF patients with PCOS.
View Article and Find Full Text PDFEffect of Gonadotropin-Releasing Hormone Agonist Pre-Treatment on Outcomes of Fresh and Frozen Embryo Transfers in Women With Adenomyosis: A Retrospective Cohort Study With Literature Review.
BJOG
April 2025
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, People's Republic of China.
Objectives: To investigate the effect of gonadotropin-releasing hormone agonist (GnRHa) pre-treatment on the clinical outcomes of fresh and frozen embryo transfers (ETs and FETs, respectively) in infertile patients with adenomyosis.
Design: Retrospective cohort study with literature review.
Setting: Peking University First Hospital.
The Current Understanding of Molecular Mechanisms in Adenomyosis-Associated Infertility and the Treatment Strategy for Assisted Reproductive Technology.
Int J Mol Sci
August 2024
Department of Obstetrics and Gynecology, Linkou Medical Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Article Synopsis
- Adenomyosis, a condition affecting the uterus, impairs fertility by disrupting the normal processes important for embryo implantation and development, influenced by various hormones and inflammatory factors.
- Current research indicates that adenomyosis is linked to lower pregnancy rates, higher miscarriage rates, and poor outcomes for both mothers and newborns.
- Treatment options, including medications and surgery, show promise in enhancing reproductive outcomes, especially when using GnRHa protocols, which can improve implantation rates and assist with natural conception efforts.